Merus N.V. (MRUS)
| Market Cap | 7.20B |
| Revenue (ttm) | 56.23M |
| Net Income (ttm) | -385.52M |
| Shares Out | 75.84M |
| EPS (ttm) | -5.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 497,667 |
| Open | 95.30 |
| Previous Close | 94.90 |
| Day's Range | 94.74 - 95.30 |
| 52-Week Range | 33.19 - 95.30 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 93.72 (-1.24%) |
| Earnings Date | Oct 31, 2025 |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumor... [Read more]
Financial Performance
In 2024, Merus's revenue was $36.13 million, a decrease of -17.78% compared to the previous year's $43.95 million. Losses were -$215.33 million, 39.0% more than in 2023.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for MRUS stock is "Buy." The 12-month stock price target is $93.72, which is a decrease of -1.24% from the latest price.
News
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRID...
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: G MAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“ Purchaser...
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m...
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Months after cancer drug trial, Merus agrees to be bought at 41% premium
Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...
Merus to Present at the 2025 Wells Fargo Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody...
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-len...
Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions
NEW YORK--(BUSINESS WIRE)--Merus Global Investments (“Merus”), a multi-strategy investment partnership, today unveiled its refreshed website and announced a series of senior promotions and strategic a...
One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed
TAMPERE, Finland, July 03, 2025 (GLOBE NEWSWIRE) -- The energy storage facility delivered by Merus Power to Lappeenranta, Finland, has been completed and put into market use on 15 May 2025. The energy...
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative...
Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer
CNBC's Angelica Peebles sits down with Merus CEO Dr. Bill Lundberg to discuss the company's recent positive results in head & neck cancer and what he sees for the future of bispecific antibody drugs
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-len...
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus to Present at Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UT...